News
Avicenna Alliance interview for ANSYS
For the Avicenna Alliance, in silico medicine is the obvious connect between the promise of big …
Avicenna Alliance at BIN@Sheffield conference
On 30th October to 1st November 2017, the Bin@Sheffield “How can digitalisation transform how we work and live?” will take place in Cutlers Hall, Sheffield, UK.
Smaller budget for Horizon 2020 in 2018?
Horizon 2020, the European Union research program, runs the risk of having a smaller budget for the coming year 2018. The Council of the European Union which represents the executive governments of the EU's member states did not accept the European Commission's budget proposal from this summer. What will this mean for the position of European research?
Brexit – what is the current status (on research)?
The primary principle of the EU27 remains that before talks on the future can begin, the negotiations on an orderly withdrawal must first make enough progress to prove that the UK is a credible negotiating partner. An orderly exit procedure for the EU concerns mainly the questions of financial settlement, citizens’ rights and the situation of Northern Ireland.
Avicenna Alliance at BMES Conference in Washington- video available!
In the week of 15-18 May 2017 the Avicenna Alliance was in Washington DC, following an invitation by the FDA and by the staff of Senator T. Cochran to discuss the role of in silico medicine. The Delegation consisted of Avicenna Alliance Members, an EMA Representative, FDA Representatives, US-Avicenna Contacts, US Senate Staff and the RPP Group.
FDA confirms its investment in modeling and simulation for improving drug development
Scott Gottlieb commissioner of the USA Food & Drug Administration has recently written an article for the FDA Blog “FDA Voice” on the impact of the 21st Century Cures Act, which authorised $6.3 billion in additional funding, part of which is dedicated to research and drug development.